Asuragen: Cutting pancreatic surgeries
Patients with pancreatic cancer and pancreatitis present with similar symptoms, and are often given ultrasound tests to confirm the presence or absence of lesions. About 15% of these tests are inconclusive, and as a result patients often undergo partial or full pancreatectomies, about 10% of which are unnecessary.
Asuragen Inc. hopes its minimally invasive miRNA diagnostic will change that, reducing the number of highly invasive procedures.
While Asuragen initially will target the 15% of inconclusive cases, CEO Matt